MA49055B1 - Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf - Google Patents
Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnfInfo
- Publication number
- MA49055B1 MA49055B1 MA49055A MA49055A MA49055B1 MA 49055 B1 MA49055 B1 MA 49055B1 MA 49055 A MA49055 A MA 49055A MA 49055 A MA49055 A MA 49055A MA 49055 B1 MA49055 B1 MA 49055B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- modulators
- imidazole derivatives
- tnf activity
- fused pentacyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
L'invention concerne un composé de formule (i), ou un sel pharmaceutiquement acceptable de celui-ci, qui sont de puissants modulateurs de l'activité du tnfa humain, et trouvent ainsi une utilité dans le traitement et/ou la prévention de diverses affections humaines, notamment les troubles auto-immuns et inflammatoires ; les troubles neurologiques et neurodégénératifs ; la douleur et les troubles nociceptifs ; les troubles cardiovasculaires ; les troubles métaboliques ; les troubles oculaires ; et les troubles oncologiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17168027 | 2017-04-25 | ||
PCT/EP2018/060489 WO2018197503A1 (fr) | 2017-04-25 | 2018-04-24 | Dérivés d'imidazole pentacycliques fusionnés utilisés en tant que modulateurs de l'activité du tnf |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49055A MA49055A (fr) | 2021-05-05 |
MA49055B1 true MA49055B1 (fr) | 2021-12-31 |
Family
ID=58632834
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49055A MA49055B1 (fr) | 2017-04-25 | 2018-04-24 | Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf |
MA57699A MA57699B1 (fr) | 2017-04-25 | 2018-08-24 | Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA57699A MA57699B1 (fr) | 2017-04-25 | 2018-08-24 | Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf |
Country Status (33)
Country | Link |
---|---|
US (3) | US10980814B2 (fr) |
EP (2) | EP3615534B1 (fr) |
JP (2) | JP7083358B2 (fr) |
KR (1) | KR102565132B1 (fr) |
CN (1) | CN110582495B (fr) |
AR (1) | AR111426A1 (fr) |
AU (1) | AU2018259040B2 (fr) |
BR (1) | BR112019020314A2 (fr) |
CA (1) | CA3058980A1 (fr) |
CL (1) | CL2019002875A1 (fr) |
CO (1) | CO2019012856A2 (fr) |
CR (1) | CR20190526A (fr) |
DK (1) | DK3615534T3 (fr) |
EA (1) | EA039049B1 (fr) |
ES (2) | ES2893807T3 (fr) |
HR (1) | HRP20211927T1 (fr) |
HU (1) | HUE056593T2 (fr) |
IL (1) | IL269890B (fr) |
LT (1) | LT3615534T (fr) |
MA (2) | MA49055B1 (fr) |
MX (1) | MX2019012443A (fr) |
MY (1) | MY197212A (fr) |
PE (1) | PE20200662A1 (fr) |
PH (1) | PH12019502182A1 (fr) |
PL (2) | PL3615534T3 (fr) |
PT (2) | PT3615534T (fr) |
RS (1) | RS62596B1 (fr) |
SG (1) | SG11201908871SA (fr) |
SI (1) | SI3615534T1 (fr) |
TW (1) | TWI801378B (fr) |
UY (1) | UY37700A (fr) |
WO (1) | WO2018197503A1 (fr) |
ZA (1) | ZA201906255B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201892144A1 (ru) * | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf |
CN113227097B (zh) * | 2018-10-24 | 2023-09-08 | Ucb生物制药有限责任公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6359008B2 (ja) | 2012-06-11 | 2018-07-18 | ユーシービー バイオファルマ エスピーアールエル | Tnf−アルファ調節ベンゾイミダゾール |
EA028722B1 (ru) * | 2012-07-13 | 2017-12-29 | Юсб Байофарма Спрл | Производные имидазопиридина в качестве модуляторов активности tnf |
GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN107108672B (zh) | 2014-10-03 | 2019-11-08 | Ucb生物制药私人有限公司 | 稠合的五环咪唑衍生物 |
UY36630A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
-
2018
- 2018-04-24 WO PCT/EP2018/060489 patent/WO2018197503A1/fr unknown
- 2018-04-24 PL PL18719178T patent/PL3615534T3/pl unknown
- 2018-04-24 ES ES18719178T patent/ES2893807T3/es active Active
- 2018-04-24 US US16/497,217 patent/US10980814B2/en active Active
- 2018-04-24 LT LTEPPCT/EP2018/060489T patent/LT3615534T/lt unknown
- 2018-04-24 PT PT187191788T patent/PT3615534T/pt unknown
- 2018-04-24 EP EP18719178.8A patent/EP3615534B1/fr active Active
- 2018-04-24 PT PT211893789T patent/PT3939980T/pt unknown
- 2018-04-24 RS RS20211403A patent/RS62596B1/sr unknown
- 2018-04-24 MX MX2019012443A patent/MX2019012443A/es unknown
- 2018-04-24 CN CN201880025894.6A patent/CN110582495B/zh active Active
- 2018-04-24 SI SI201830491T patent/SI3615534T1/sl unknown
- 2018-04-24 EA EA201992407A patent/EA039049B1/ru unknown
- 2018-04-24 BR BR112019020314A patent/BR112019020314A2/pt unknown
- 2018-04-24 TW TW107113777A patent/TWI801378B/zh active
- 2018-04-24 MY MYPI2019005903A patent/MY197212A/en unknown
- 2018-04-24 PE PE2019002028A patent/PE20200662A1/es unknown
- 2018-04-24 PL PL21189378.9T patent/PL3939980T3/pl unknown
- 2018-04-24 SG SG11201908871S patent/SG11201908871SA/en unknown
- 2018-04-24 ES ES21189378T patent/ES2956555T3/es active Active
- 2018-04-24 HU HUE18719178A patent/HUE056593T2/hu unknown
- 2018-04-24 HR HRP20211927TT patent/HRP20211927T1/hr unknown
- 2018-04-24 MA MA49055A patent/MA49055B1/fr unknown
- 2018-04-24 CR CR20190526A patent/CR20190526A/es unknown
- 2018-04-24 JP JP2019556874A patent/JP7083358B2/ja active Active
- 2018-04-24 EP EP21189378.9A patent/EP3939980B1/fr active Active
- 2018-04-24 AU AU2018259040A patent/AU2018259040B2/en active Active
- 2018-04-24 KR KR1020197034032A patent/KR102565132B1/ko active IP Right Grant
- 2018-04-24 CA CA3058980A patent/CA3058980A1/fr active Pending
- 2018-04-24 DK DK18719178.8T patent/DK3615534T3/da active
- 2018-04-25 UY UY0001037700A patent/UY37700A/es not_active Application Discontinuation
- 2018-04-25 AR ARP180101067A patent/AR111426A1/es unknown
- 2018-08-24 MA MA57699A patent/MA57699B1/fr unknown
-
2019
- 2019-09-20 ZA ZA2019/06255A patent/ZA201906255B/en unknown
- 2019-09-23 PH PH12019502182A patent/PH12019502182A1/en unknown
- 2019-10-07 IL IL269890A patent/IL269890B/en unknown
- 2019-10-09 CL CL2019002875A patent/CL2019002875A1/es unknown
- 2019-11-18 CO CONC2019/0012856A patent/CO2019012856A2/es unknown
-
2021
- 2021-02-15 US US17/176,018 patent/US20210252012A1/en not_active Abandoned
-
2022
- 2022-05-31 JP JP2022088172A patent/JP7299382B2/ja active Active
-
2023
- 2023-02-27 US US18/175,030 patent/US20230250105A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40770B1 (fr) | Dérivés d'imidazoles pentacyclic fusionnés | |
MA38949A1 (fr) | Forme saline d'hydrochlorure pour inhibition d'ezh2 | |
MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
EA201892153A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
TR201909614T4 (tr) | Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri. | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA43828B1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
TR201910983T4 (tr) | Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. | |
CR20200291A (es) | Composiciones y métodos para el tratamiento de enfermedades metabólicas | |
EA201792686A1 (ru) | Производные индазола в качестве модуляторов активности tnf | |
MA49055B1 (fr) | Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf | |
MA50069A (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39253B1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
EA201892142A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
MA46965B1 (fr) | Modulateurs de gamma ror (rory) | |
EA201892149A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |